文献速递白血病造血干细胞移植与细胞治疗

内源性TCR促进CD19-CAR-T细胞体内持久性优于CRISPR/Cas9介导的TCR敲除CAR

Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.
PubMed 文献 · Blood · 2020-01-01

研究在原发性T细胞中联合CRISPR/Cas9介导的TCRβ链敲除与含4-1BB共刺激域的第二代逆转录病毒CAR转导,获得TCR-KO-CAR-T细胞。该细胞在CD19靶标识别后强激活、增殖并特异性杀伤,且消除了同种异体反应性;但在患者来源儿童ALL异种移植模型中,内源性TCR与CAR共表达的T细胞体内持久性更优并显著延长白血病控制。

要点

  • CRISPR/Cas9敲除TCRβ链联合4-1BB CAR转导可制备高功能TCR-KO-CAR-T细胞。
  • TCR-KO-CAR-T细胞强激活、增殖并特异性杀伤CD19靶细胞,且同种异体反应性被强烈消除。
  • 患者来源儿童ALL异种移植模型中TCR-KO-CAR-T细胞控制白血病负荷并改善生存,但内源性TCR共表达者持久性与白血病控制更优。

核心结论

  • CRISPR/Cas9介导TCR敲除的抗CD19 CAR-T细胞在无同种异体反应性下具有高抗白血病功能,是非匹配第三方过继T细胞转移的有前景候选者,但体内长期持久性在内源性TCR存在时更好。
  • 内源性TCR对反应持久性具有重要作用,但代价是同种异体反应性。

研究设计与样本

  • 在原发性T细胞中联合CRISPR/Cas9介导的TCRβ链敲除与含4-1BB共刺激域的第二代逆转录病毒CAR转导。
  • 采用患者来源儿童急性淋巴细胞白血病(ALL)异种移植模型及NALM6白血病细胞系的第二个体内模型进行验证。

主要发现

  • TCR-KO-CAR-T细胞在CD19靶标识别后表现出强激活(CD25、干扰素γ)、增殖和特异性杀伤。
  • TCR-KO-CAR-T细胞具有中央记忆与效应记忆T细胞的平衡表型。
  • 与表达TCR的T细胞相比,TCR敲除强烈消除同种异体反应性。
  • 在患者来源儿童ALL异种移植模型中,TCR-KO-CAR-T细胞明确控制CD19+白血病负荷并改善体内生存。
  • 内源性TCR与CAR共表达导致T细胞持久性更优并显著延长体内白血病控制,经NALM6第二个体内模型确认。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Anti-CD19 chimeric antigen receptor (CAR) T cells showed significant antileukemic activity in B-precursor acute lymphoblastic leukemia (ALL). Allogeneic, HLA-mismatched off-the-shelf third-party donors may offer ideal fitness of the effector cells, but carry the risk of graft-versus-host disease. Knockout (KO) of the endogenous T-cell receptor (TCR) in CD19-CAR-T cells may be a promising solution. Here, we induced a CRISPR/Cas9-mediated KO of the TCRβ chain in combination with a second-generation retroviral CAR transduction including a 4-1BB costimulatory domain in primary T cells. This tandem engineering led to a highly functional population of TCR-KO-CAR-T cells with strong activation (CD25, interferon γ), proliferation, and specific killing upon CD19 target recognition. TCR-KO-CAR-T cells had a balanced phenotype of central memory and effector memory T cells. KO of the endogenous TCR in T cells strongly ablated alloreactivity in comparison with TCR-expressing T cells. In a patient-derived xenograft model of childhood ALL, TCR-KO-CAR-T cells clearly controlled CD19+ leukemia burden and improved survival in vivo. However, coexpression of endogenous TCR plus CAR led to superior persistence of T cells and significantly prolonged leukemia control in vivo, confirmed by a second in vivo model using the leukemia cell line NALM6. These results point toward an essential role of the endogenous TCR for longevity of the response at the price of alloreactivity. In conclusion, anti-CD19 CAR T cells with a CRISPR/Cas9-mediated TCR-KO are promising candidates for nonmatched third-party adoptive T-cell transfer with high antileukemic functionality in the absence of alloreactivity, but long-term persistence in vivo is better in the presence of the endogenous TCR.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Stenger D, Stief TA, Kaeuferle T, et al. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. Blood. 2020. PMID: 32483603. doi:10.1182/blood.2020005185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。